BOXL vs LGND vs PRGO vs PRSO

For growth investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger pick with 27.

3% revenue growth year-over-year, versus -19. 6% for Boxlight Corporation (BOXL). Analysts rate Ligand Pharmaceuticals Incorporated (LGND) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ligand Pharmaceuticals Incorporated (LGND) delivered a total return of +61.

0%, compared to -99. 3% for Peraso Inc. (PRSO). Over 10 years, the gap is even starker: LGND returned +73. 0% versus PRSO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ligand Pharmaceuticals Incorporated (LGND) is the lower-risk stock at 0.

99β versus Boxlight Corporation's 1. 25β — meaning BOXL is approximately 26% more volatile than LGND relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 33% for Boxlight Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ligand Pharmaceuticals Incorporated (LGND) is pulling ahead at 27.

3% versus -19. 6% for Boxlight Corporation (BOXL). On earnings-per-share growth, the picture is similar: Peraso Inc. grew EPS 86. 3% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PRSO leads at 36. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ligand Pharmaceuticals Incorporated (LGND) is the more profitable company, earning -2.

4% net margin versus -73. 6% for Peraso Inc. — meaning it keeps -2. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -85. 3% for PRSO. At the gross margin level — before operating expenses — LGND leads at 93. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 23. 6x for Ligand Pharmaceuticals Incorporated — 18. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

In this comparison, PRGO (9.

8% yield) pays a dividend. BOXL, LGND, PRSO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

18), 9. 8% yield). Both have compounded well over 10 years (PRGO: -77. 7%, BOXL: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BOXL (Technology) and LGND (Healthcare) and PRGO (Healthcare) and PRSO (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BOXL is a small-cap quality compounder stock; LGND is a small-cap high-growth stock; PRGO is a small-cap income-oriented stock; PRSO is a small-cap quality compounder stock. PRGO pays a dividend while BOXL, LGND, PRSO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.